Servier Presents Updated Translational Data from Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib tablets) in Patients with IDH Mutant Low-Grade Glioma at ASCO 2021
Discover our news
Servier Highlights Novel Approaches to Treating Cancer at the ASCO and EHA 2021 Annual Meetings
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Cholangiocarcinoma
Servier Completes Acquisition of Agios Pharmaceuticals’ Oncology Business
Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
Taiho Oncology and Servier To Present Data on LONSURF® (trifluridine and tipiracil) at 2021 ASCO Gastrointestinal Cancers Symposium (ASCO GI)
Servier Announces a Collaboration to Explore Immune Checkpoint Signaling in Cancer
Servier to Acquire Agios Pharmaceuticals’ Oncology Business